310P Clinical characteristics and real-world progression-free survival of patients with EGFR mutation positive non-small cell lung cancer treated with afatinib as first-line: A retrospective cohort study from Indonesia

Abstract

The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) afatinib, demonstrated superiority to chemotherapy as a first-line treatment and improved survival in non-small cell lung cancer (NSCLC) patients with EGFR mutations. This study aimed to investigate the clinical risk factors affecting progression-free survival (PFS) of patients treated with first-line afatinib in Indonesia.